Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis

Objectives: Despite the growing evidence of efficacy, scarce information exists regarding the cost of tadalafil to improve the functional classes of pediatric patients with pulmonary arterial hypertension. This study aims to determine the cost-utility of tadalafil compared sildenafil to treat pediat...

Full description

Autores:

Buendía Rodríguez, Jefferson Antonio
Lindarte Rincón, Erika Fernanda
Guerrero Patiño, Diana

Tipo de recurso:

Article of investigation

Fecha de publicación:

2023

Institución:

Universidad de Antioquia

Repositorio:

Repositorio UdeA

Idioma:

eng

OAI Identifier:

oai:bibliotecadigital.udea.edu.co:10495/47839

Acceso en línea:

https://hdl.handle.net/10495/47839

Palabra clave:

Cost-Benefit Analysis
Análisis Costo-Beneficio
Phosphodiesterase 5 Inhibitors
Inhibidores de Fosfodiesterasa 5
Pulmonary Arterial Hypertension
Hipertensión Arterial Pulmonar
Sildenafil Citrate
Citrato de Sildenafil
Tadalafil
Tadalafilo
Niño
Child
https://id.nlm.nih.gov/mesh/D000068581
https://id.nlm.nih.gov/mesh/D003362
https://id.nlm.nih.gov/mesh/D058986
https://id.nlm.nih.gov/mesh/D000081029
https://id.nlm.nih.gov/mesh/D000068677
https://id.nlm.nih.gov/mesh/D002648
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades

Rights

openAccess

License

http://creativecommons.org/licenses/by-nc-nd/4.0/